Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04287829
Title Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients (PEMMELA)
Acronym PEMMELA
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors The Netherlands Cancer Institute
Indications
Therapies
Age Groups: adult | senior
Covered Countries NLD

Facility Status City State Zip Country Details
Antoni van Leeuwenhoekziekenhuis (NKI-AVL) Amsterdam Noord-Holland 1066 CX Netherlands Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field